Context: A recent study published in The New England Journal of Medicine reported that the antiviral drug Ensitrelvir significantly reduced symptomatic COVID-19 infections among exposed household contacts.
Antiviral Drug EnsitrelvirAbout Antiviral Drug Ensitrelvir :What It Is?
Ensitrelvir is an oral antiviral drug that inhibits the SARS-CoV-2 main protease (3C-like protease/Mpro), an enzyme essential for viral replication.
To provide a safer and longer-lasting oral antiviral option without requiring booster drugs like ritonavir.
Oral Antiviral Drug : Can be administered orally, making it suitable for outpatient and household use.
Context: A recent study published in The New England Journal of Medicine reported that the antiviral drug Ensitrelvir significantly reduced symptomatic COVID-19 infections among exposed household contacts.
Antiviral Drug Ensitrelvir
About Antiviral Drug Ensitrelvir :
What It Is?
Ensitrelvir is an oral antiviral drug that inhibits the SARS-CoV-2 main protease (3C-like protease/Mpro), an enzyme essential for viral replication.
By blocking this protease, the drug prevents the coronavirus from processing viral proteins required for multiplication inside human cells.
Aim:
To treat mild-to-moderate COVID-19 infections and reduce viral transmission after exposure.
To provide a safer and longer-lasting oral antiviral option without requiring booster drugs like ritonavir.
Key Features:
Protease Inhibitor Mechanism: Targets the SARS-CoV-2 main protease (Mpro), preventing viral replication.
Targets the SARS-CoV-2 main protease (Mpro), preventing viral replication. Oral Antiviral Drug : Can be administered orally, making it suitable for outpatient and household use.
Can be administered orally, making it suitable for outpatient and household use. Broad Variant Activity: Showed effectiveness against multiple SARS-CoV-2 variants, including Omicron.
Showed effectiveness against multiple SARS-CoV-2 variants, including Omicron. Better Safety Profile: Remains longer in the bloodstream without requiring ritonavir and avoids the bitter aftertaste associated with some COVID antivirals.
Remains longer in the bloodstream without requiring ritonavir and avoids the bitter aftertaste associated with some COVID antivirals. SCORPIO-PEP Trial Findings: Reduced symptomatic COVID-19 incidence from 9% to 2.9% among exposed household contacts.
Significance:
Represents a major advancement in post-exposure prophylaxis for COVID-19, especially for high-risk household contacts.
Provides a potential starting point for future antiviral treatments against related betacoronaviruses like SARS and MERS.
Relevance in UPSC Exam Syllabus
